CAI vs GMED
Caris Life Sciences, Inc. vs Globus Medical — AI-powered side-by-side comparison
CAI
Caris Life Sciences, Inc.
57
Watch
VS
GMED
Globus Medical
71
Buy
| Metric | CAI | GMED |
|---|
| AI Score |
57
|
71
|
| Price |
$23.12
|
$85.12
|
| P/E Ratio |
62.22×
|
21.45×
|
| ROE |
-93.2%
|
11.8%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
69.7%
|
68.5%
|
| Debt / Equity |
0.76×
|
0.02×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
86.2
|
75.9
|
| Beta |
0.678
|
0.954
|
| Expected Upside |
—
|
+0.1%
|
AI Committee View
Current Innellis committee reasoning for CAI versus GMED.
GMED leads by 14 points.
GMED scores 71/100 (Buy) versus CAI at 57/100 (Watch).
CAI Committee View
50% agreement
4 analysts
The committee is genuinely divided. Macro Analyst sees a compelling case — vix regime is low -- calm backdrop supports risk-taking. Risk Analyst remains cautious — bollinger bandwidth of 63.0% signals elevated volatility. This disagreement is itself the signal — the setup is not clean in either direction.
Bull Case
- MACD histogram positive -- bullish momentum — Technical
- VIX regime is low -- calm backdrop supports risk-taking — Macro
- Market regime is bullish (Bull market -- normal position sizing) — Macro
Bear Case
- RSI at 86 is in overbought territory — Technical
- Price trading above the upper Bollinger Band -- stretched — Technical
- Bollinger bandwidth of 63.0% signals elevated volatility — Risk
GMED Committee View
75% agreement
4 analysts
The primary driver is 5 consecutive earnings beats -- consistent execution. The main limiting factor is rsi at 76 is in overbought territory. The committee is constructive but not yet at full conviction.
Bull Case
- 5 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- MACD histogram positive -- bullish momentum — Technical
Bear Case
- RSI at 76 is in overbought territory — Technical
- Price trading above the upper Bollinger Band -- stretched — Technical